TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Left ventricular volumes and contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants With No Follicle Rupture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change in Mean Heading perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median Hepatic Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in muscle glycogen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood non-esterified fatty acid (NEFA) concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: skin aging benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: skin brightening benefits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement of BPH symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Subjects Who Failed to Maintain a Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who abstain from smoking
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: PCR-Corrected ACPR at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of intestinal microbial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean lumen diameter of paired grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum stenosis of paired grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of vein graft thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity during placement of the regional anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Without Mucosal Ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Bronchopulmonary Dysplasia (BPD) or Death
Endpoint domain: Mortality/survival
Primary endpoint: Average Number of Parathyroid Glands Identified With High Confidence Per Patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall accrual
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: attrition using the Mental Component Summary of Short Form-36
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Alteration in the rate of bile acid synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HIV result by Western Blot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline systolic blood pressure after 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline systolic blood pressure after 2 and 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with good or very good quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patients' perceptions of risks and benefits of early identification of dementia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reticulocyte haemoglobin content (RET-He)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cost per adolescent girl and young women on pre-exposure prophylaxis
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incremental cost-effectiveness ratio per incidence HIV case averted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Behavioral Inattention Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Observed adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in PrEP adherence levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in condom use and sexual practice
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in number of couples completing clinical protocol for PrEP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Seroconversion rate of antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seropositivity rate of antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of the radiological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Parkinson's Disease Questionnaire-39 (PDQ-39)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in the Timed Up-and-Go (TUG) Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Gait Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with an anti-diphtheria concentration ≥0.01 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with an anti-tetanus concentration ≥0.01 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects with an anti-polio type 1 titer ≥ 8 (1/dilution)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With AUX I and AUX II Detected in Their Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Magnetization transfer ratio dynamic mapping of lesions and normal appearing brain tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pain level measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores of UDS FTLD Module Tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic Expansion Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the levels of pain and discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the difficulty in mastication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the difficulty in swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all cause deaths
Endpoint domain: Mortality/survival
Primary endpoint: SAR access
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: percent change in HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: percent change in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fugl-Meyer Motor Upper Extremity Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized blood flow between fetal twins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects with dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of dose interruptions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Paroxysmal Atrial Fibrillation (PAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of clinical autoimmunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in Knee Joint Symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Gait Speed (m/s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Gait Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Trunk Lean on the Prosthetic versus Non-Prosthetic Side of the Body
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved detection in the visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SARS-CoV-2 specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dichotomized lifetime alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized lifetime tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized lifetime marijuana use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dichotomized lifetime opioid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past 30-day alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Past 30-day tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skin elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Myocardial Blush Grade 3 (MBG3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ST-Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hamilton Rating Scale for Depression change score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ≥2 log10 Decline of HDV RNA From Baseline at End of Treatment (EOT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability of danoprevir: Area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of ritonavir: Area under the concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in skin health and appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic effects of BMS-708163
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in the number of RP attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychophysical well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Were Clinical Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensibility of markers for vitality diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of markers for vitality diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 8-hydroxydeoxyguanosine (8-OHdG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of pancreatic cystic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum methylphenidate plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scar height
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Less BK Infection Episodes Based on Viruria Results
Endpoint domain: Adverse events/effects
Primary endpoint: Less BK Infection Episodes Based on Viremia Results
Endpoint domain: Adverse events/effects
Primary endpoint: Less BK Infection Episodes Based on Nephropathy Results
Endpoint domain: Adverse events/effects
Primary endpoint: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD4+ and CD8+ Th1 Cellular Immunogenicity on Day 180
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Solicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: FGF23 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reading of LD and ULD acquisitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma levels of MMP2 and MMP9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biomarker Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic yield of cryo biopsy vs. CT guided biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in bioelectrical impedance analysis (BIA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Respiratory disturbances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Cochin score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in corneal epithelial defect area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Onset of at least one complication requiring a specific treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Recurrent Ischemic Stroke
Endpoint domain: Mortality/survival
Primary endpoint: New Brain Infarct or Recurrent Stroke
Endpoint domain: Mortality/survival
Primary endpoint: RSV nasopharyngeal swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: RSV lung/thorax microbiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: RSV lung/thorax histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Migraine Headache Pain at 2 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Most-Bothersome Symptom at 2 Hours Post Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coronary atherosclerosis plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Outcome Questionnaire -45.2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence, type, and severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Phosphorylation of Akt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion of the microcirculation of the skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: additional etiological diagnosis of intellectual disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Participants Achieving ACR 20% Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Pain Score at Endpoint
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in Behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma level of Doxapram and ketodoxapram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow-mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet activation measured by CD62P expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical Image Quality (CIQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific T-cell proliferation/cytokine secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: EEG quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of NCE images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptation duration of antibiotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity of postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: intraoperative bleeding amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in haemoglobin and hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Negative Biopsies at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Relative bioavailability of MTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular alteration in breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraoperative nausea vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Fatty acid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the curve (AUC) of ceftriaxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough level of metronidazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response by symptom measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response measured by ELISPOT testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: death in hospital
Endpoint domain: Mortality/survival
Primary endpoint: Change in disinhibition scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in frequency of food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in level of faecal Clostridium difficile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average of Total Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Meal tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma levels of glycine-conjugated trihydroxycholanic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of postpartum hypertension complication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 6 Month Progression-free Survival (PFS6)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Disposition Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Steady state area under the concentration time curve (AUC) of zidovudine (ZDV)-MP, ZDV-TP, and dTTP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure (AUC) of nelfinavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV RNA viral titers, alanine aminotransferase (ALT) levels, CD4+, and HIV-RNA viral titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Generalized Anxiety Disorder Symptoms at 14-Day Post-Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Generalized Anxiety Disorder Symptoms at 6-Week Post-Randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Perseverative Cognitions at 14-Day Post-Treatment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline Perseverative Cognitions at 6-Week Post-Randomization
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intrauterine fetal death
Endpoint domain: Mortality/survival
Primary endpoint: Still birth
Endpoint domain: Mortality/survival
Primary endpoint: NICU admission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: HBV DNA load in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Work Time Missed Due to Health Problem
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Change From Baseline in Impairment While Working Due to Health Problem
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Change From Baseline in Overall Work Impairment Due to Health Problem
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean Change From Baseline in Overall Activity Impairment Due to Health Problem
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Enamel White Spot Lesions index surface scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Laser fluorescence values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity/Mortality
Endpoint domain: Mortality/survival